Posts Tagged 'diabetic ketoacidosis'

Trouble for Diabetes Drug Makers?

invokana and farxiga mdls to move forwardKnown as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.

Unfortunately, this relatively new class of drugs has already allegedly caused enough harm to warrant FDA action ...

continue reading...

Woman Claims Invokana Caused Her Diabetic Ketoacidosis

A Georgia woman has filed an Invokana ketoacidosis lawsuit claiming Janssen Pharmaceutical’s drug caused her to develop the potentially life-threatening blood condition known as diabetic ketoacidosis.

Invokana (canagliflozin) is one of a new line of diabetes medications called sodium-glucose cotransport-2 (SLGT2) inhibitors. Unlike traditional insulin treatments, SGLT2 inhibitors regulate the body’s blood sugar levels by reabsorbing excess glucose in the kidneys and disposing of it through urine. Less than two years after Invokana, Farxiga, and Jardiance reached ...

continue reading...

Invokana Class-Action Lawsuit Filed in Canada

The diabetes drug Invokana has become the focus of a national class-action lawsuit in Canada, CBC Nova Scotia reports. According to a statement filed in the Ontario Supreme Court of Justice, the lead plaintiff alleges that Janssen Pharmaceuticals’ new sodium-glucose cotransporter-2 (SGLT2) inhibitor was responsible for her kidney failure.

SGLT2 inhibitors, a new line of type 2 diabetes medications, work by directing excess blood sugars to be eliminated through urine. But not long after they reached the ...

continue reading...

Case Report Highlights Diabetic Ketoacidosis Risk with SGLT2 Inhibitors

Another case report links sodium-glucose co-transporter 2 (SGLT2) inhibitors like Invokana to diabetic ketoacidosis, a severe and potentially fatal condition wherein the body produces too many blood acids. The article, published in the journal Practical Diabetes, presents the case of a 58-year-old woman who suffered severe diabetic ketoacidosis after her twice-daily insulin regimen was replaced by dapagliflozin.

SGLT2 inhibitors, the new class of type 2 diabetes medication introduce in 2013, were first linked to ketoacidosis ...

continue reading...

First Study on SGLT2 Inhibitor Use in Type 1 Diabetics Shows Increased Diabetic Ketoacidosis

sglt2 inhibitor results fall shortAccording to a Medscape article, the results of the first-ever Phase 2 study of sodium-glucose cotransporter-2 (SGLT2) inhibitor use in type 1 diabetes patients have been reported—and they may not be as reassuring as many had hoped. The data were presented at the European Association for the Study of Diabetes (EASD) 2015 Meeting by Robert R. Henry, MD, chief of the Division of Endocrinology and Metabolism at the University of ...

continue reading...